CCR6 作为银屑病的一个可能治疗靶点。
CCR6 as a possible therapeutic target in psoriasis.
机构信息
National Institutes of Health, National Institute of Allergy and Infectious Diseases, Laboratory of Molecular Immunology, Inflammation Biology Section, Bethesda, MD 20892, USA.
出版信息
Expert Opin Ther Targets. 2010 Sep;14(9):911-22. doi: 10.1517/14728222.2010.504716.
IMPORTANCE OF THE FIELD
Psoriasis is a common, chronic autoimmune disease of the skin. Despite a number of effective treatments, new therapies are needed with enhanced efficacy, safety and convenience. Chemokine receptors are GPCRs that control leukocyte trafficking, and like other GPCRs, are good potential drug targets. The chemokine receptor CCR6 is expressed on the T(H)17 subset of CD4(+) T cells, which produces IL-17A/F, IL-22, TNF-alpha and other cytokines, and which has been implicated in the pathogenesis of psoriasis. CCR6 and its ligand, CCL20/MIP-3alpha, are highly expressed in psoriatic skin and CCR6 is necessary for the pathology induced in a mouse model of psoriasis-like inflammation.
AREAS COVERED IN THIS REVIEW
This review summarizes the evidence for the importance of the IL-23/T(H)17 axis, and in particular CCR6 and CCL20 in psoriasis, dating from 2000 to the present, and discusses the possibility of inhibiting CCR6 as a treatment for the disease.
WHAT THE READER WILL GAIN
The review informs the reader of the current thinking on the mechanisms of inflammation in psoriasis and the possible roles for CCR6 (and CCL20) in disease pathogenesis.
TAKE HOME MESSAGE
We conclude that CCR6 should be investigated as a potential therapeutic target in psoriasis.
重要性领域
银屑病是一种常见的慢性自身免疫性皮肤病。尽管有许多有效的治疗方法，但仍需要新的治疗方法，以提高疗效、安全性和便利性。趋化因子受体是控制白细胞迁移的 GPCR，与其他 GPCR 一样，是潜在的良好药物靶点。趋化因子受体 CCR6 表达在 CD4+T 细胞的 T(H)17 亚群上，该亚群产生 IL-17A/F、IL-22、TNF-α 和其他细胞因子，并且与银屑病的发病机制有关。CCR6 和其配体 CCL20/MIP-3alpha 在银屑病皮肤中高度表达，CCR6 是在银屑病样炎症的小鼠模型中诱导的病理学所必需的。
这篇综述总结了自 2000 年以来关于 IL-23/T(H)17 轴，特别是 CCR6 和 CCL20 在银屑病中的重要性的证据，并讨论了抑制 CCR6 作为治疗该疾病的可能性。
读者将获得什么
该综述使读者了解了银屑病炎症机制的最新研究进展，以及 CCR6（和 CCL20）在疾病发病机制中的可能作用。
结论
我们认为 CCR6 应该作为银屑病的潜在治疗靶点进行研究。
Zotero 插件